Octreotide市場規模、佔有率和成長分析：按劑型、適應症、通路、最終用戶、產品類型和地區分類－2026-2033年產業預測

2024 年全球Octreotide市場價值為 18.2 億美元，預計到 2025 年將成長至 19.1 億美元，到 2033 年將成長至 28.5 億美元，在預測期（2026-2033 年）內複合年成長率為 5.12%。

受神經內分泌腫瘤發生率上升以及醫生日益傾向於採用能提高患者依從性的製劑的推動，全球Octreotide市場正顯著擴張。Octreotide最初僅限於特定醫院藥房，如今已發展成為一種廣泛分銷的產品，主要地區緩釋注射劑的法規核准反映了精準醫療的趨勢。保險公司對注射用生物製劑的接受度提高也促進了市場需求，使Octreotide成為內分泌治療領域創新的象徵。此外，門診輸液服務和攜帶式自動注射器的出現，使患者更容易在家中接受治療，從而推動了短效和長效緩釋製劑的研發。新興市場生產商和經銷商之間的合作進一步提高了藥物的可近性和可負擔性。

全球Octreotide市場成長要素

荷爾蒙分泌性神經內分泌腫瘤發生率的上升顯著增加了對Octreotide作為標靶治療的需求，促使臨床醫生將該藥物納入各種治療方案，以緩解症狀和抑制腫瘤進展。這一趨勢導致患者數量增加，醫療專業人員在各種臨床環境中應用Octreotide。因此，處方量不斷成長，透過擴大治療用途和提高專科醫生對該藥物的認知度，為市場擴張創造了機會。此外，Octreotide在改善病患生活品質方面的顯著療效也進一步促進了其在多學科醫療體系中的應用。

全球Octreotide市場的限制因素

由於生產流程複雜且市場競爭有限，Octreotide的全球市場面臨嚴峻挑戰。這導致其價格飆升，加重了醫療預算和患者的負擔。因此，尤其是在價格敏感市場，謹慎納入藥物核准標準和更嚴格的報銷政策阻礙了該藥物的廣泛應用。醫療服務提供者可能會選擇更經濟的替代藥物或延遲治療。此外，經濟因素可能導致臨床醫生在推薦Octreotide時猶豫不決，最終導致處方量減少。這種經濟障礙影響了預算決策，使人們傾向於選擇更具成本效益的治療方案。

全球Octreotide市場趨勢

全球Octreotide市場正經歷一個顯著的趨勢：治療適應症的擴展。這一成長主要源於臨床醫生對有效緩解症狀的信心增強以及患者需求的增加，從而導致奧曲肽在難治性消化道出血和各種激素紊亂等疾病中的仿單標示外使用日益增多。因此，生產商正加大對標靶臨床研究的投入，拓展產品平臺，並加強與專家的合作。這種策略性舉措旨在提高市場滲透率，同時在多個治療領域建立穩定的收入基礎，從而加強與全球相關人員的長期合作關係。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Octreotide市場規模：按劑型分類

• 速釋注射劑
• 長效（LAR）緩釋製劑
• 皮下植入式

全球Octreotide市場規模：依適應症分類

• 肢端肥大症
• 類癌腫瘤
• 靜脈曲張出血
• 腹瀉（VIP腫瘤）

全球Octreotide市場規模：依分銷管道分類

• 醫院藥房
• 專科藥房

全球Octreotide市場規模：依最終用戶分類

• 醫院
• 內分泌診所

全球Octreotide市場規模：依產品類型分類

• 品牌商品（Sandostatin）
• 生物相似藥

全球Octreotide市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novartis AG（Sandostatin）
• Sun Pharmaceutical
• Mylan（Viatris）
• Teva Pharmaceutical
• Dr. Reddy's Laboratories
• Hikma Pharmaceuticals
• Pfizer Inc.
• Cambrex Corporation
• Lonza Group
• Bachem Holding
• BCN Peptides
• PolyPeptide Group
• Fresenius Kabi
• Cipla Ltd.
• Amneal Pharmaceuticals
• Lupin Limited
• Aurobindo Pharma
• Glenmark Pharmaceuticals
• Sandoz（Novartis）
• Hospira（Pfizer）

結論與建議

Global Octreotide Market size was valued at USD 1.82 Billion in 2024 and is poised to grow from USD 1.91 Billion in 2025 to USD 2.85 Billion by 2033, growing at a CAGR of 5.12% during the forecast period (2026-2033).

The global octreotide market has expanded significantly, driven by the rising incidence of neuroendocrine tumors and the increasing physician adoption of formulations that improve patient compliance. Originally confined to niche hospital pharmacies, octreotide has evolved into a widely distributed product, with depot injections gaining regulatory approval across major regions, reflecting the shift toward personalized medicine. The growing acceptance of injectable biologics by payers has also bolstered demand, transforming octreotide into a symbol of innovation in endocrine therapy. Additionally, the advent of outpatient infusion services and portable autoinjectors has enabled patients to receive treatments conveniently at home, fostering the development of both short-acting and long-acting depot products. Collaborations between manufacturers and distributors in emerging markets further enhance accessibility and affordability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Octreotide market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Octreotide Market Segments Analysis

Global octreotide market is segmented by formulation, indication, distribution, end-user, product type and region. Based on formulation, the market is segmented into Immediate Release (IR) Injectable, Long-Acting Release (LAR) Depot and Subcutaneous Implant. Based on indication, the market is segmented into Acromegaly, Carcinoid Tumors, Variceal Bleeding and Diarrhea (VIPoma). Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Hospitals and Endocrinology Clinics. Based on product type, the market is segmented into Branded (Sandostatin) and Biosimilars. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Octreotide Market

The rising prevalence of hormone-secreting neuroendocrine tumors has significantly enhanced the demand for octreotide as a targeted treatment, prompting clinicians to incorporate this medication into various treatment protocols for alleviating symptoms and suppressing tumor progression. This trend has led to a growing patient population, encouraging healthcare professionals to employ octreotide across a range of clinical environments. Consequently, there is an increase in prescribing activities, presenting opportunities for market expansion through heightened therapeutic applications and greater awareness among specialists. Furthermore, the acknowledged effectiveness of octreotide in enhancing patients' quality of life is further driving its integration within multidisciplinary care frameworks.

Restraints in the Global Octreotide Market

The global octreotide market faces significant challenges due to its intricate manufacturing process and limited competition, leading to high pricing that creates pressure on both healthcare budgets and patients. As a result, there tends to be cautious formulary placements and restrictive reimbursement policies that hinder the drug's broader adoption, especially in markets sensitive to pricing. Health care providers may opt for more affordable alternatives or postpone initiating therapy, while economic considerations can deter clinicians from recommending octreotide, ultimately causing a decline in prescription volumes. This financial barrier influences budgeting decisions, resulting in a preference for more cost-effective treatments.

Market Trends of the Global Octreotide Market

The Global Octreotide market is experiencing a notable trend towards the expanding landscape of therapeutic indications. This surge is fueled by rising clinician confidence and patient demand for effective symptom relief, leading to increased off-label usage for conditions such as refractory gastrointestinal bleeding and various hormonal disorders. As a result, manufacturers are committing more resources to targeted clinical research, broadening their product pipelines, and fostering collaborations with specialty physicians. This strategic approach not only enhances market penetration but also aims to establish a stable revenue base across diverse therapeutic areas, thereby solidifying long-term stakeholder relationships across the globe.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Octreotide Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Immediate Release (IR) Injectable
• Long-Acting Release (LAR) Depot
• Subcutaneous Implant

Global Octreotide Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Acromegaly
• Carcinoid Tumors
• Variceal Bleeding
• Diarrhea (VIPoma)

Global Octreotide Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Octreotide Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Endocrinology Clinics

Global Octreotide Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Branded (Sandostatin)
• Biosimilars

Global Octreotide Market Size & CAGR (2026-2033)

• North America (Formulation, Indication, Distribution, End-User, Product Type)
  • US
  • Canada
• Europe (Formulation, Indication, Distribution, End-User, Product Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Formulation, Indication, Distribution, End-User, Product Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Formulation, Indication, Distribution, End-User, Product Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Formulation, Indication, Distribution, End-User, Product Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Sandostatin)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BCN Peptides
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PolyPeptide Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hospira (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations